Budesonide/Formoterol Teva Pharma B.V. 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
1 issued on 
Decision 
Issued2 / 
amended 
on 
Information 
affected3 
SmPC, Annex 
II, Labelling 
and PL 
IB/0004/G 
This was an application for a group of variations. 
17/09/2015 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). 
Opinions are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). 
The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union 
 
  
 
 
 
 
 
 
 
                                                
IA/0002/G 
This was an application for a group of variations. 
24/07/2015 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
II/0001/G 
This was an application for a group of variations. 
26/03/2015 
n/a 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Budesonide/Formoterol Teva Pharma B.V.  
EMA/708876/2015 
Page 2/2 
  
  
 
 
 
 
 
 
 
 
  
